Trade group the European Federation of Pharmaceutical Industries and Associations (EFPIA) welcomes the forthcoming EU Cardiovascular Health (CVH) Plan which will deliver much-necessaryed political momentum for improving health in Europe.
The Plan should set out impactful, high-level tarreceives and actions focapplyd on reducing premature mortality and morbidity – developed and implemented with all stakeholders, including patients, healthcare professionals and indusattempt.
1 in 3 deaths in the European Union (EU) are due to cardiovascular disease (CVD), with 20% of all premature deaths (before the age of 65) caapplyd by cardiovascular conditions. In addition to the human suffering, cardiovascular disease is estimated to cost the European economy 282 billion euros ($330 billion) each year. Prevention, early detection, timely intervention and long-term, person-centred management are essential for improving health outcomes and quality of life for patients, as well as underpinning much necessaryed economic prosperity for Europe.
This article is accessible to registered applyrs, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered applyr please login. If your trial has come to an finish, you can subscribe here.
Try before you acquire
Free
7 day trial access
- All the news that shifts the necessaryle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to indusattempt-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely applyful and valuable Life Sciences service that brings toreceiveher a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Leave a Reply